Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifolates: current developments

E A Rayl1, G Pizzorno

  • 1Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8032, USA.

Cancer Treatment and Research
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE.

Gene therapy·2011
Same author

p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction.

Cancer research·2001
Same author

The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.

Cancer research·2001
Same author

Uridine phosphorylase association with vimentin. Intracellular distribution and localization.

The Journal of biological chemistry·2001
Same author

A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.

Cancer journal (Sudbury, Mass.)·2000
Same author

Results of retroviral and adenoviral approaches to cancer gene therapy.

Stem cells (Dayton, Ohio)·2000

Researchers are developing new anticancer drugs to overcome methotrexate (MTX) resistance. These novel therapies, based on mechanistic understanding, show promising preclinical activity and are advancing to clinical trials.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Methotrexate (MTX) resistance is a significant challenge in cancer therapy.
  • Understanding the mechanisms of MTX resistance is crucial for developing effective treatments.

Purpose of the Study:

  • To review and summarize strategies for overcoming MTX resistance.
  • To highlight novel anticancer drug classes developed through mechanistic approaches.

Main Methods:

  • Mechanistic investigations into MTX resistance.
  • Preclinical evaluation of newly developed anticancer agents.

Main Results:

  • Identification of diverse mechanisms contributing to MTX resistance.
  • Development of several new classes of anticancer drugs with varied mechanisms of action.

Related Experiment Videos

  • Promising preclinical activity observed for these novel drug candidates.

    • Conclusions:

    • Mechanistic insights have successfully guided the development of novel anticancer drugs.
    • These new drug classes represent a promising advancement in combating MTX resistance.
    • Further clinical testing is warranted to establish the efficacy and safety of these agents.